

## **IN THE CLAIMS**

This listing of claims will replace all prior versions, and listing of the claims in the application.

### **Listing of Claims:**

**Claims 1-90 (canceled)**

**Claims 91-123 (withdrawn)**

**Claim 124 (currently amended)** An isolated polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to the complement of a DNA sequence encoding a *Neisseria* surface protein, wherein said *Neisseria* surface protein:

- (i) is resistant to proteinase K, and
- (ii) has an apparent molecular weight of 22 kDa, and
- (iii) is stained by Coomassie blue,

wherein said polypeptide is antigenic.

**Claim 125 (currently amended)** The isolated polypeptide of claim 124, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO:2.

**Claim 126 (withdrawn)**

**Claim 127 (previously presented)** The isolated polypeptide of claim 124, comprising amino acids 31 to 55 of SEQ ID NO:2 and which is antigenic.

**Claim 128 (previously presented)** The isolated polypeptide of claim 124, comprising amino acids 51 to 86 of SEQ ID NO:2 and which is antigenic.

**Claim 129 (previously presented)** The isolated polypeptide of claim 124, comprising amino acids 110 to 140 of SEQ ID NO:2 and which is antigenic.

**Claim 130 (cancelled)**

**Claims 131-132 (withdrawn)**

**Claim 133 (previously presented)** A pharmaceutical composition comprising the polypeptide of claim 124.

**Claim 134 (previously presented)** The pharmaceutical composition of claim 133, which is a vaccine.

**Claim 135 (previously presented)** The pharmaceutical composition of claim 134, comprising a pharmaceutical excipient.

**Claim 136 (previously presented)** A method of preventing infection by a *Neisseria* pathogen, comprising administering an effective amount of the vaccine of claim 134.

**Claim 137 (previously presented)** The method according to claim 136, wherein said pathogen is a *Neisseria meningitidis*.

**Claims 138-169 (withdrawn)**

**Claim 170 (previously presented)** The vaccine of claim 134, which further comprises an adjuvant.

**Claim 171 (previously presented)** The vaccine of claim 170, wherein the adjuvant is a liposome adjuvant.

**Claim 172 (previously presented)** The method of claim 136, wherein the vaccine further comprises an adjuvant.

**Claim 173 (previously presented)** The method of claim 172, wherein the adjuvant is a liposome adjuvant.

**Claim 174 (currently amended)** An isolated polypeptide from the surface of *Neisseria* bacteria which

- (i) is resistant to proteinase K, ~~and~~
  - (ii) has an apparent molecular weight of 22 kDa, and
  - (iii) is stained by Coomassie blue, and
- wherein said polypeptide is antigenic.

**Claim 175 (previously presented)** The isolated polypeptide of claim 174, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO:2.

**Claim 176 (previously presented)** The isolated polypeptide of claim 124, wherein said polypeptide consists of the amino acid sequence of SEQ ID NO:2.

**Claim 177 (previously presented)** The isolated polypeptide of claim 124, consisting of amino acids 51 to 86 of SEQ ID NO:2 and which is antigenic.

**Claim 178 (previously presented)** The isolated polypeptide of claim 124, comprising amino acids 110 to 140 of SEQ ID NO:2 and which is antigenic.

**Claim 179 (previously presented)** The isolated polypeptide of claim 124, consisting of amino acids 31 to 55 of SEQ ID NO. 2 and which is antigenic.

**Claim 180 (previously presented)** The isolated polypeptide of claim 124 having an antigenicity effective for use as a vaccine.

**Claim 181 (previously presented)** The isolated polypeptide of claim 174 having an antigenicity effective for use as a vaccine.

**Claim 182 (new)** An isolated polypeptide of claim 124, wherein said polypeptide is capable of eliciting antibodies that are specific to said polypeptide

**Claim 183 (new)** An isolated polypeptide of claim 124, wherein said polypeptide is capable of eliciting bacteriolytic antibodies against *Neisseria meningitidis*.

**Claim 184 (new)** An isolated polypeptide of claim 174, wherein said polypeptide is capable of eliciting antibodies that are specific to said polypeptide

**Claim 185 (new)** An isolated polypeptide of claim 174, wherein said polypeptide is capable of eliciting bacteriolytic antibodies against *Neisseria meningitidis*.

**Claim 186 (new)** An isolated polypeptide of claim 124, wherein said hybridizing is at 42°C with a solution comprising 50% formamide.

**Claim 187 (new)** An isolated polypeptide of claim 124, which is free of any other *Neisseria meningitidis* polypeptide.

**Claim 188 (new)** A composition comprising an isolated polypeptide of claim 187, and a pharmaceutically acceptable excipient.

**Claim 189 (new)** An isolated polypeptide of claim 174, which is free of any other *Neisseria meningitidis* polypeptide.

**Claim 190 (new)** A composition comprising an isolated polypeptide of claim 189, and a pharmaceutically acceptable excipient.

**Claim 191(new)** A vaccine, comprising a polypeptide of claim 187 and an adjuvant.

**Claim 192 (new)** A method of manufacturing a vaccine, comprising

formulating a polypeptide of claim 187 with an adjuvant.

**Claim 193 (new)** A vaccine, comprising a polypeptide of claim 190 and an adjuvant.

**Claim 194 (new)** A method of manufacturing a vaccine, comprising formulating a polypeptide of claim 189 with an adjuvant.

**Claim 195 (new)** An isolated polypeptide of claim 124, wherein said polypeptide is produced recombinantly.

**Claim 196 (new)** An isolated polypeptide of claim 174, wherein said polypeptide is produced recombinantly.